ArticleFrontiers in medicine2026
Optimized deep learning ensemble using Fast Osprey algorithm for accurate lymphoblastic leukemia detection.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and validation of an explainable XGBoost model for early mortality prediction in pediatric sepsis.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Acute Lymphoblastic Leukemia (ALL) is a hematological malignancy, which is life-threatening and demands rapid and precise diagnosis to either enhance or worsen the survival chances. Traditional diagnostic methods, especially the manual microscopic examination, are labor-intensive and subject to inter-observer variability. Even though deep learning models have been shown to achieve good performance in automated detection, single-model structures tend to be prone to overfitting and under-generalize to heterogeneous datasets, with low interpretability. Hence, an effective and responsive computer-aided diagnostic (CAD) platform is required to promote the reliability of diagnostics. Methods: We introduce a new ensemble-based model that can be trained on a combination of several state-of-the-art convolutional neural networks (CNNs), such as EfficientNetB3, EfficientNetV2B3, and EfficientNetV2B1, and optimized with Fast Osprey Optimization (FOO), a bio-inspired algorithm that dynamically assigns optimal ensemble weights. An extensive dataset was formed through the combination of all publicly available datasets, and thereafter, data augmentation was used to address the issue of class imbalance and to improve the generalization of the model. The FOO algorithm is a model contribution optimization algorithm that is used in the training process to enhance predictive robustness and computational efficiency. Results: The proposed FOO-Ensemble model outperformed all baseline architectures. It achieved an accuracy of 97.76%, a precision of 98.13%, a recall of 97.71%, and an F1-score of 97.83%. In addition to improved classification performance, the ensemble approach reduced inference time compared to individual models. Comparative analysis with recent state-of-the-art methods further demonstrated the robustness, scalability, and superior generalization capability of the proposed framework. Conclusion: The results demonstrate the usefulness of using deep learning ensembles with bio-inspired optimization in trustworthy ALL detection. A dynamic weighting mechanism improves stability and minimizes the risks of overfitting of standalone models. The higher diagnostic quality and computational capability have high chances of real clinical application. The suggested FOO-Ensemble framework is a scalable and reliable CAD model that will be able to assist hematopathologists in making early and accurate diagnoses of ALL, which will ultimately result in the provision of better patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.